Neon Therapeutics’ $100 Million Initial Public Offering


Goodwin advised Neon Therapeutics on the deal

Neon Therapeutics (“NTGN”), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, closed its public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, for gross proceeds of approximately $100 million.

Goodwin advised with a team including Mitchell S. Bloom, Stuart M. Cable (Picture) and Joseph C. Theis, Jr.

Involved fees earner: Mitchell Bloom – Goodwin Procter; Stuart Cable – Goodwin Procter; Joseph Theis Jr. – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Neon Therapeutics;

Author: Ambrogio Visconti